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Summan The factors that determine progression of cervical intraepithelial neoplasia (CIN) to squamous cell
carcinoma (SCC) are unknown. Cigarette smoking is an independent risk factor for cervical neoplasia.
suggesting that polymorphism at detoxicating enzyme loci such as cvtochrome P450 CYP2D6 and glutathione
S-transferase GSTM I mav determine susceptibility to these cancers. We have studied the frequencies of
genotypes at these loci in women suffering low-grade CIN. high-grade CIN and SCC. A non-cancer control
group uas pros ided by women with normal cervical histology suffering menorrhagia. Comparison of the
frequency distributions of the CYP'D6 PM. HET and EM genotypes (G-*A transition at intron 3 exon 4 and
base pair deletion in exon 5) revealed no significant differences between the menorrhagia and SCC groups.
Frequency distributions in the menorrhagia group. however, were significantlv different (P <0.04) from those
in the lou- and high-grade CIN groups. Thus. the proportion of EM was significantly larger (P <0.03) and of
HET generally lower. We found that the frequency of GSTMI null in the menorrhagia and case groups was
not significantly different. Interactive effects of enzyme genotypes with cigarette smoking were studied bv
comparing the multinomial frequency distributions of CYP2D6 EM GSTMI null smoking over mutuallv
exclusive categories. These showed no significant differences between the menorrhagia group and SCC or
low-grade CIN groups. The frequency distribution in high-grade CIN. however. was significantlv different to
that in the menorrhagia group and in both SCC and low-grade CIN groups. This study has identified, for the
first time. an inherited characteristic in women with high-grade CIN who appear to be at reduced risk of SCC.
Thus. women with CYP2D6 EM who smoke have increased susceptibility to high-grade CIN but are less likelv
to progress to SCC. possibly because they effectively detoxify an unidentified chemical involved in mediating
disease progression.
The natural history of squamous cell cancer of the cervix
(SCC) is uncertain. Convention proposes a progression of
cervical intraepithelial neoplasia (CIN) that culminates in
invasive disease (McIndoe et al.. 1984; Anderson. 1991).
While low-grade CIN (I II) is associated with increased risk
of SCC. the risk appears small. and less than 5% of cases
will progress to high-grade lesions (CINIII). In contrast. it is
estimated that 36-7600 of high-grade lesions will progress to
SCC over 20 years. The factors determining progression or
regression of lesions are unknown but are likely to include
both genetic and environmental influences (Mclndoe et al..
1984: Anderson. 1991).
Risk factors for cervical neoplasia include human papillo-
mavirus (HPV). altered immune defence and diet. Epidemio-
logical data identifying cigarette smoking as an independent
risk factor complement studies showing that cigarette-derived
compounds such as cotinine and nicotine are concentrated in
cervical mucus and that this mucus can be mutagenic
(Winkelstein. 1990; Gram et al.. 1992; Burger et al., 1993).
Further. DNA from cervical epithelial cells of smokers con-
tains adducts of the type expected from reaction with
polycyclic aromatic hydrocarbons and aromatic amines, both
constituents of smoke. Women with abnormal cervical
cytology demonstrate the highest proportions of adducts
(Simons et al.. 1993). Data showing that metastatic progres-
sion of primary cervical cancers may be accompanied by
GC-*TA transversions in p53 also suggest a role for car-
cinogens such as benzpyrene and aflatoxin B (Crook et al.,
1992), although mutations in the hotspot regions of this gene
appear to be infrequent in cervical carcinomas (Paquette et
al.. 1993: Busby-Earle et al.. 1994).
Indivliduals differ in their susceptibility to cancer. and
identification of predisposing genes could allow identification
of women with CIN at risk of SCC. While susceptibility is
multifactorial. polxrmorphisms in enzymes catalysing the
detoxication of carcinogens will be significant if allelic pro-
ducts have different efficiencies. The phase 1 cytochrome
P450 (CYP) enzymes catalyse the modification of various
chemicals to reactive. sometimes carcinogenic. intermediates
(e.g. epoxides) that phase 2 enzymes convert to excretable
compounds. Several CYP genotypes have been associated
with cancer nrsk (Idle et al.. 1992: Wolf et al.. 1992: Nakachi
et al.. 1993). These include the CYP2D6 poor metaboliser
(PM) genotype that results from several gene-inactivating
mutations (Gough et al.. 1990: Wolf et al.. 1992). Some. but
not all. studies have linked the PM genotype with decreased
risk of lung cancer. suggesting the benefit of slower forma-
tion of reactive intermediates (Idle et al.. 1992: Wolf et al..
1992). Significantly. the PM genotype may also enhance risk:
thus. studies in leukaemia and malignant melanoma show
increased frequency of mutant alleles implicating impaired
detoxication of an unidentified chemical (Wolf et al.. 1992).
The phase 2 glutathione S-transferases are also relevant.
Thus. GSTM 1 isoforms catalyse the detoxication of geno-
toxic epoxides (e.g. benzpyrene). GSTM 1 genotypes anse
from combinations of the GSTMI*O. GSTMI*A and
GSTMI*B alleles. GSTMI*O is deleted and homozygotes
(GSTM 1 null) express no protein (Seidegard et al.. 1988:
Pearson et al.. 1993: Strange. 1993). The importance of
GSTM 1 in mediating cancer risk is indicated bv studies
showing that GSTM1 null is associated with increased risk of
some cancers. although data in lung cancer are conflicting
(Seidegard et al.. 1988: Zhong et al.. 1991: Strange. 1993).
Support also comes from recent studies shoWing that the
heterozygote GSTM1 A B genotype is protective in basal cell
carcinoma of skin. suggesting that two expressed alleles con-
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fer better protection than GSTMI*O heterozygosity
(Heagerty et al.. 1994).
Subjects at high risk of cancer may be better identified by
combinations of GSTM 1 and CYP2D6 genotypes. Thus.
homozygotes for GSTMI*O and a rare CYPlAl allele who
smoke have a greatly enhanced risk of lung cancer (Nakachi
et al., 1993). We now report CYP2D6 and GSTM1 genotype
frequencies in women with normal cervical histology, low-
and high-grade CIN and SCC. Our aim was to test the
hypothesis that women with GSTM1 null CYP2D6 extensive
metaboliser (EM) are most likely to develop SCC. As
cigarette smoke contains carcinogenic substrates for these
enzvmes. we expect this effect to be most obvious in smokers.
Patients and methods
Patients
Unrelated Caucasian women with CIN. SCC or normal cer-
vical histology were recruited. with Ethics Committee ap-
proval. in the North Staffordshire Hospital. Each gave
informed consent. Smoking status was assessed by history.
Non-smokers had never smoked. Smokers currently smoked.
or had previously smoked, at least 10 cigarettes a day for at
least 5 years. Urine cotinine levels usually confirmed the
history. but in some patients urine was only obtainable
immediately post-operatively and levels were low even in
subjects who admitted to smoking.
The CIN group comprised 94 women (mean age 37.1
years) with high-grade CIN (CIN III) and 85 women (mean
age 38.6 years) with low-grade CIN (CIN I or CIN II). They
presented with abnormal cervical cytology requiring colpo-
scopic assessment and subsequently underwent excisional
biopsy. Standard morphological criteria were used to diag-
nose and grade CIN lesions. CINI and II were combined as
the diagnosis of CINIII can be made with confidence. but
differentiating CINI from II is less certain (Ismail et al..
1989; Anderson. 1991). The SCC group comprised 77 women
(mean age 48.5 years. majority FIGO stage lb) who presented
de novo or were under surveillance following completion of
treatment. Genotype frequencies in these case groups were
compared with those in 180 women (mean age 43.0 years)
with menorrhagia who had undergone hysterectomy. This
group comprised 97 women with normal uterine histology
and 83 with leiomyoma without atypia. The women had a
minimum 5 year history of normal cervical cytology and had
not undergone cervical surgery. In all cases cervical histology
showed no e'Vidence of neoplasia.
Genotype frequencies were also studied in 190 unrelated
North Staffordshire Caucasians (mean age 61 years; 70%
female). Samples were obtained at post-mortem. from hos-
pital wards or out-patient clinics from subjects without
clinical or histological evidence of malignant or inflammatory
disease.
Identification ofCYP2D6 and GSTMJ genotypes
The two mutant CYP2D6 alleles (G-*A transition at intron
3 exon 4 and base pair deletion in exon 5) were identified in
separate polymerase chain reaction (PCR) assays. Together
these assays are about 90% predictive of phenotype (Gough
et al.. 1990; Wolf et al.. 1992). The G-*A transition was
identified using intron 3 exon 4 primers followed by BstNI
digestion. Amplified DNA from homozygotes (PM genotype)
was not digested. The base pair deletion in exon 5 was
identified using primers to exon 5 intron 5 followed by HpaII
digestion. Amplified DNA from homozygotes for the mutant
allele (PM genotype) was digested (Gough et al., 1990; Wolf
et al.. 1992).
The GSTM 1 null genotype was identified in leucocyte
DNA using a modified amplification refractory mutation
system (ARMS)-based PCR (Fryer et al., 1993; Heagerty et
al.. 1994). Amplification was carried out using primer sets to
intron 6 exon 7 and exon 4,exon 5 of GSTMI and, as
positive control. frglobin primers.
Statistical analysis
r tests were used to examine for homogeneity between cases
and controls. Since some genotype frequencies were small,
the StatXact-Turbo statistical package was used to obtain
exact P-values.
As three factors (CYP2D6 EM, GSTM 1 null, smoking)
were studied, the influence on disease susceptibility of each
(alone and in combination in pairs and triplets) was studied
by comparing frequency distributions over the resulting
mutually exclusive categories. Thus, in any patient group the
GSTMI null subjects comprise individuals who are GSTM1
null only, GSTM 1 null/CYP2D6 EM only, GSTM 1 null/
smoking only and GSTMI null/CYP2D6 EM/smoking. The
advantage of this approach is that it allows identification of
those factors (alone and in combination) that contribute
most to observed differences between cases and controls.
Results
Genotype frequencies in the patient groups were analysed in
the order CYP2D6 alone, CYP2D6 EM with smoking,
GSTM1 null and both genes in combination with smoking.
Frequency ofCYP2D6 genotipes
Frequency distributions of CYP2D6 genotypes in women
with normal uterine histology or leiomyoma were not
signficantly different. For example. frequencies of the
CYP2D6 PM G-*A transition were 5.2% and 4.8% respec-
tively. Data from the two groups were, therefore, combined
(Table I). The frequencies of the CYP2D6 genotypes (G-*A
transition) in the menorrhagia group (Table I) were similar
to those in Sheffield controls (Wolf et al., 1992), and the
frequencies of both the G-*A transition and exon 5 deletion
Table I Frequency of CYP2D6 genotypes in women with SCC and
CIN
CYP2D6 genot)jpe (O%
EM HET PM Total
scc
G-*A transition 57.9 34.2 7.9 76
Base pair deletion 97.3 2.7 0 75
Both alleles 57.3 33.3 9.3 75
High-grade CIN
G-*A transition' 72.8b 21.7c 5.4 92
Base pair deletion 95.6 4.4 0 90
Both allelesd 70.1e 23.0f 6.9 87
Lo%-grade CIN
G-*A transition 66.3 26.5s 7.2 83
Base pair deletion 100.0 0 0 82
Both allelesh 66.7' 25.9' 7.4 81
MUenorrhagia group
G-*A transition 55.9 39.1 5.0 179
Base pair deletion 94.5 6.1 0 166
Both alleles 51.2 41.6 7.2 166
"Frequency distribution EM, HET, PM genotypes vs menorrhagia
group (X22 = 8.530. P = 0.014). bProportion with EM genotype vs
menorrhagia group (X2 = 6.697, P = 0.0097). 'Proportion with HET
genotype vs menorrhagia group (Xj = 7.669, P = 0.056). dFrequency
distribution EM, HET, PM genotypes vs menorrhagia group;
= 6.827, P = 0.0329). eProportion with EM genotype vs menorr-
hagia group (x, = 5.484, P = 0.0192). 'Proportion with HET
genotype vs menorrhagia group (X2 = 7.844, P = 0.005). gProportion
with HET genotype vs menorrhagia group (Xi = 3.418. P = 0.0645).
hFrequency distribution EM, HET, PM genotypes vs menorrhagia
group (j, = 6.5519, P = 0.0378). 'Proportion with EM genotype vs
menorrhagia group (xy =4.949. P = 0.0261). 'Proportion with HET
genotype vs menorrhagia group (x, = 3.307, P = 0.069). EM, exten-
sive metabolisers who are homozygotes for the wild-type sequence at
the mutation site tested or heterozygotes for the gene deletion; HET,
heterozygotes for one of the mutations examined. PM, homozygotes
and heterozygotes for G-+A transition or base pair deletion or
heterozygotes for one of these mutations and the gene deletion.706 A.P. WARWICK et al.
in these subjects and the North Staffordshire controls were
similar.
Table I shows the frequencies of CYP2D6 genotypes
(G-*A transition. the exon 5 deletion and these mutations
together) in the CIN. SCC and menorrhagia groups. Fre-
quenc) distributions of genotypes in the menorrhagia group
and SCC were not different. but those in the menorrhagia
group and high-grade CIN were significantly different for the
G-*A transition alone and both mutations combined. Thus,
the frequency of EM was significantly larger and of HET
(heterozygotes for one of the mutations examined) signifi-
cantly lower (Table I). The frequency distributions of EM,
HET and PM (both mutations) in the menorrhagia and
low-grade CIN groups were also significantly different (Table
I). Thus. the proportion of patients with EM was signifi-
cantly larger in low-grade CIN. while that of HET (each
mutation) approached significance (Table I). The frequencies
of the wild-type allele. calculated from the data in Table I.
were: menorrhagia group. 0.72: low-grade CIN. 0.80: high
grade CIN 0.82: and SCC. 0.74.
The importance of CYP2D6 EM (both mutations) in com-
bination with smoking in the cases and menorrhagia subjects
was studied by comparing multinomial frequency distribu-
tions in mutually exclusive categories (Table II). The fre-
quency distribution in the menorrhagia group was signifi-
cantly different to that in the low- and high-grade CIN
groups but not SCC cases. The distribution in the high-grade
CIN group was significantly different from that in both the
SCC and low-grade CIN case groups as well as the menor-
rhagia group. Interestingly. the proportion of high-grade
CIN subjects who had the EM genotype and smoked was
significantly greater than in the other case groups (Table II).
Frequency ofGST.VI genotypes
The frequencies of GSTM 1 null in women with normal
uterine histology or leiomyoma (60% and 58% respectively)
were not significantly different, and data from the two groups
were, therefore. combined (Table III). Although Table III
shows the frequency of GSTM1 null in this menorrhagia
group to be rather higher than previously reported for some.
but not all. non-cancer controls (Seidegard et al.. 1988;
Board et al.. 1990; Zhong et al., 1991; Strange. 1993;
Heagerty et al.. 1994), the frequency of this genotype was not
significantly different to that in the North Staffordshire con-
trols or CIN or SCC patients.
Frequenci ofcombinations ofGSTMJ null, CYP2D6 and
smoking
The importance of the CYP2D6 EM (both mutations) and
GSTM1 null in combination in smoking and non-smoking
cases and menorrhagia subjects was studied by comparing
multinomial frequency distributions in mutually exclusive
categories (Table IV).
Comparison of these frequency distnrbutions showed no
significant differences between the menorrhagia group and
SCC or low-grade CIN or between patients with SCC and
those with low-grade CIN. The frequency distribution of
genotypes in high-grade CIN, however, was significantly
different to that in the menorrhagia subjects and in those
with both SCC and low-grade CIN.
Table IV allows identification of the combinations of the
three factors (i.e. smoking, GSTMI null and CYP2D6 EM)
in mutually exclusive groups that demonstrated significantly
different frequencies in the case and menorrhagia groups.
The importance of the EM genotype and smoking was shown
by the significantly increased frequency of this combination
in multinomial frequency distributions in high-grade CIN
compared with low-grade CIN and SCC (Table IV).
In keeping with the data in Table III. the GSTM1 null
genotype did not appear to be an important factor in deter-
mining susceptibility to cervical neoplasia. Thus, the frequen-
cies of the genotype alone, in combination with smoking, in
combination with CYP2D6 EM or in combination with both
smoking and CYP2D6 EM in the menorrhagia or three case
groups were not significantly increased.
Di~
We have examined the hypothesis that susceptibility to SCC
is influenced by polymorphism at CYP2D6 and GSTM1. In
particular we wished to determine whether the putatively
high-risk combination, GSTM1 null,'CYP2D6 EM smoking.
identifies women most likely to suffer SCC. in which case the
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Table II Frequency of combinations of CYP2D6 EM and smoking in case and control groups.
The influence of CYP2D6 EM and smoking. individually and in combination. on susceptibility
to CIN and SCC was studied by comparing their frequency distributions over mutually exclusive
groups
High-grade Low-grade
Menorrhagiad (00 SCC ( CIV'4' ( %v CIN !%
Neither 16.9 21.9 10.2 14.8
CYP2D6 EM onlv 22.5 24.7 12.5 35.8
Smoking only 30.9 21.9 21.6 17.3
EM + smoking only 29.8 31.5 55 7-h- 32.1
100 100 100 100
Numbers of subjects 178 73 88 81
'Frequency distribution in menorrhagia vs low-grade CIN (T, = 7.828. P = 0.0497). bFre-
quency distribution in menorrhagia vs high-grade CIN (i3 = 16.96. P = 0.0007). cFrequency
distribution in high-grade CIN vs low-grade CIN (T23 = 16.08. P = 0.0011). dFrequency distribu-
tion in high-grade CIN vs SCC (/23 = 12.00. P = 0.0074). 'Frequency distribution in high-grade
CIN vs SCC and low-grade CIN (126 = 21.57. P = 0.0014). 'Frequency of the combination
CYP2D6 EM smoking in high-grade CIN vs menorrhagia (i, = 15.64. P =0.001. odds
ratio = 2.963). 'Frequency of the combination CYP2D6 EM smoking in high-grade CIN vs
low-grade CIN (, = 8.572. P = 0.0034. odds ratio = 2.658). hFrequency of the combination
CYP2D6 EM smoking in high-grade CIN vs SCC (/2 = 8.480. P = 0.0036. odds ratio = 2.731).CYP2D6 AND GSTMI GENOTYPES IN CERVICAL CANCER 707
Table IV Frequency of combinations of GSTM I null and CYP2D6 EM in smoking and
non-smoking cases in mutually exclusive groups. The influence of CYP2D6 EM. GSTMI null
and smoking. individually and in combination, on susceptibilitv to CIN and SCC was studied bv
comparing their frequency distributions over mutually exclusive groups. The table shows the
percentage of subjects in the case and control groups demonstrating each of the eight possible
combinations of the three factors
High-grade Low-grade
AUenorrhagia !% SCC (%0 CLsV__xd (%0 CIN 00%
Noone 6.8 17.8'f- 4.5 6.2
GSTMI null onlv 9.6 4.1 5.7 9.9
CYP2D6 EM onlv 7.3 11.0 8.0 12.3
Smoking on1N 14.1 6.8 11.4 7.4
Null + smoking onlI 16.9 15.1 10.2 9.9
EM + smoking on1N 13.0 13.7 29.5h 1'.3
EM + GSTMI null onlv 15.3 13.7 4.5 22.
EM + null + smoking only 16.9 17.8 26.1 19.8
100 100 100 100
Numbers of subjects 177 73 88 81
'Frequency distribution in high-grade CIN vs menorrhagia (r- = 20.7. P = 0.0037). 'Fre-
quenc) distribution in high-grade CIN vs SCC (/- = 18.4. P = 0.01). cFrequencv distribution in
high-grade CIN is low-grade CIN (;- = 19.4. P = 0.007). dFrequencv distribution in high-grade
CIN vs SCC and low-grade CIN (Z4 = 33.6. P = 0.004). 'Frequencv of none of the three
factors in SCC s menorrhagia (/l = 5.81. P = 0.0159). 'Frequency of none of the three factors
in SCC vs high-grade CIN (,r = 6.09. P = 0.0136). gFrequenc) of none of the three factors in
SCC vs low-grade CIN (, = 3.97. P = 0.0463). 'Frequency of the combination CYP2D6
EM smoking in high-grade CIN *s SCC (, = 4.90. P = 0.0269). 'Frequenc) of the combination
CYP2D6 EM smoking in high-grade CIN s low-grade CIN (, = 6.45. P = I1. IFrequency
of the combination CYP2D6 EM GSTMI null in high-grade CIN s low-grade CIN (.'< = 10.1.
P = 0.0014).
frequency of this combination would increase progressively in
the low-grade CIN. high-grade CIN and SCC groups.
Control data were provided by subjects from North
Staffordshire and women with normal cervical histology
suffering menorrhagia. CYP2D6 genotype frequencies in
these and published controls were similar (Wolf et al., 1992).
The GSTMI null frequency in the menorrhagia group, how-
ever. was rather higher than expected. It is worth emphasis-
ing that, while allelic variation at these gene loci has
attracted attention because it may influence susceptibility to
various malignancies, the mechanism is unclear (Seidegard et
al.. 1988; Strange. 1993). Thus, while the role of GSTM1
enzymes in the detoxication of potential carcinogens such as
epoxides appears critical, their putative role in DNA repair
implies that GSTM 1 null may confer susceptibility to
inflammatory damage. However, data showing an increased
frequency of GSTM 1 null in prolactinoma, a generally
benign tumour not associated with inflammatory cell infil-
tration or exogenous chemicals, do not support either of
these hypotheses (Strange, 1993). Prolactinomas appear to be
sex hormone dependent. and while there is no obvious link
between GSTM1 and detoxication of these hormones. andro-
stene-3',17-dione is a relatively poor substrate for human mu
enzymes. It is possible that GSTM1 null is associated with an
increased risk of menorrhagia because of altered detoxication
of steroids. Similarly, for CYP2D6 much interest has centred
on susceptibility to cancer though the in vivo substrates are
unknown and data showing that the PM genotype is associ-
ated with increased susceptibility to Parkinson's disease sug-
gest the importance of endogenous neurotoxins (Smith et al..
1992).
We found no association of SCC with increased frequency
of GSTMI null or CYP2D6 EM. either individually or in
combination with smoking. Indeed, the frequency of non-
smoking,non-GSTM null non-CYP2D6 EM was signifi-
cantly greater than in the menorrhagia and low- and high-
grade CIN groups. Unexpectedly, the high-grade CIN group
demonstrated differences from the menorrhagia and other
case groups. Thus, the frequency of CYP2D6 EM was differ-
ent from the menorrhagia group and multinomial frequency
distributions were different from those in SCC and low-grade
CIN and the combination of smoking, CYP2D6 EM was
more common than in SCC or low-grade CIN. Differences in
the frequency distribution of CYP2D6 genotypes in the low-
grade CIN and menorrhagia groups were also identified.
Our data indicate that susceptibility to SCC is not
associated with GSTMI null or CYP2D6 EM. High-grade
CIN, however, is associated with an increased frequency of
smoking and CYP2D6 EM. While high-grade CIN is recog-
nised as a precursor for invasive disease, its relationship with
SCC is unclear. Thus, the incidence of high-grade CIN has
increased, while that of SCC has fallen, a process that
preceded national cervical screening (Anderson, 1991). This
indicates that not all lesions with the histopathological
appearance of high-grade CIN are premalignant. Conversely,
some SCCs may not be preceded by CIN (Anderson. 1991).
Our data suggests that women with CYP2D6 EM who
smoke have increased susceptibility to CIN but are less likely
to progress to SCC. The mechanism for this effect is un-
known but is compatible with the view that detoxicating
enzyme genotypes will increase or decrease disease risk
depending on the particular causative substrates (Smith et al..
1992; Wolf et al., 1992; Pemble et al., 1994). An explanation
for our findings would be that women with CYP2D6 EM are
at increased risk of CIN because they catalyse the rapid
formation of a carcinogenic, reactive intermediate from a
cigarette smoke-derived electrophile. These women may have
a reduced risk of SCC because the CYP2D6 EM genotype
allows effective detoxification of a further chemical involved
in mediating disease progression.
Cigarette smoke comprises a complex mixture of
chemicals. including many known carcinogens. While the
compounds involved in the development of CIN and SCC
are currently unidentified, certain tobacco-specific N-nitro-
samines are substrates for CYP2D6 and. therefore. can-
didates. Thus, exposure of a human lymphoblastoid line
expressing a CYP2D6 cDNA to the procarcinogen 4-(methyl-
nitrosamino)-1-(3-pyridyl)-l-butanone results in a con-
centration-dependent decrease in cell survival. These data
suggest that individuals with the CYP2D6 EM genotype who
smoke may form activated, mutagenic metabolites of the
procarcinogen that undergo methylation and pyridyloxo-
butylation reactions with DNA (Crespi et al.. 1991). How-
ever. while 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
and its CYP2D6-catalysed activation may be involved in the
pathogenesis of CIN. the carcinogen that is required for708 A.P. WARWICK et al.
progression to SCC and is effectively detoxicated by
CYP2D6 EM individuals is unknown.
We have described the first biochemical data identifying
women with high-grade CIN who appear to be at reduced
risk of progression to invasive disease. Recent studies show-
ing the interactive effects of genotypes at loci encoding detox-
ifying enzymes such as CYPlAl and GSTM1 (Nakachi et
al., 1993) suggest that the influence of CYP2D6 in mediating
susceptibility to cervical neoplasia will also be modified by
polymorphisms at other relevant loci.
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